JP2021035395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021035395A5 JP2021035395A5 JP2020199336A JP2020199336A JP2021035395A5 JP 2021035395 A5 JP2021035395 A5 JP 2021035395A5 JP 2020199336 A JP2020199336 A JP 2020199336A JP 2020199336 A JP2020199336 A JP 2020199336A JP 2021035395 A5 JP2021035395 A5 JP 2021035395A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- domain
- chain constant
- constant domain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 12
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 102000035160 transmembrane proteins Human genes 0.000 claims 7
- 108091005703 transmembrane proteins Proteins 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000006471 dimerization reaction Methods 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 230000002269 spontaneous effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178045A JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514875.2 | 2015-08-20 | ||
| GBGB1514875.2A GB201514875D0 (en) | 2015-08-20 | 2015-08-20 | Receptor |
| JP2019113625A JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113625A Division JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178045A Division JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021035395A JP2021035395A (ja) | 2021-03-04 |
| JP2021035395A5 true JP2021035395A5 (https=) | 2021-09-30 |
| JP7603426B2 JP7603426B2 (ja) | 2024-12-20 |
Family
ID=54292003
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
| JP2020199336A Active JP7603426B2 (ja) | 2015-08-20 | 2020-12-01 | キメラサイトカイン受容体 |
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509549A Withdrawn JP2018523485A (ja) | 2015-08-20 | 2016-08-19 | キメラサイトカイン受容体 |
| JP2019113625A Active JP6979423B2 (ja) | 2015-08-20 | 2019-06-19 | キメラサイトカイン受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178045A Withdrawn JP2022190153A (ja) | 2015-08-20 | 2022-11-07 | キメラサイトカイン受容体 |
| JP2025047075A Pending JP2025089404A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
| JP2025047074A Pending JP2025089403A (ja) | 2015-08-20 | 2025-03-21 | キメラサイトカイン受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US10800854B2 (https=) |
| EP (3) | EP4338756A3 (https=) |
| JP (6) | JP2018523485A (https=) |
| KR (2) | KR20240093884A (https=) |
| CN (2) | CN108350047A (https=) |
| AU (1) | AU2016308618B2 (https=) |
| BR (1) | BR112018003308A2 (https=) |
| CA (2) | CA2995785A1 (https=) |
| CL (2) | CL2018000415A1 (https=) |
| GB (1) | GB201514875D0 (https=) |
| HK (1) | HK1252161A1 (https=) |
| IL (2) | IL270207B2 (https=) |
| MX (2) | MX2018002042A (https=) |
| RU (1) | RU2018109350A (https=) |
| SG (1) | SG10201909759UA (https=) |
| WO (1) | WO2017029512A1 (https=) |
| ZA (1) | ZA201904156B (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| CN110191955B (zh) * | 2016-12-13 | 2024-05-31 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| AU2018329741B2 (en) * | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| GB201714718D0 (en) * | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| GB201719557D0 (en) * | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| CA3084551A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| WO2019210057A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| US11993661B2 (en) * | 2018-06-18 | 2024-05-28 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201812474D0 (en) | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
| EP3844186A4 (en) * | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| IL281428B2 (en) | 2018-09-27 | 2024-10-01 | Autolus Ltd | Chimeric antigen receptor |
| US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| AU2020232216B2 (en) * | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CA3139011A1 (en) | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Engineered t cells |
| GB201911187D0 (en) | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| KR102275668B1 (ko) | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| MX2022004326A (es) * | 2019-10-10 | 2022-07-27 | Bryologyx Inc | Método para la inducción de antígenos asociados al tumor con briostatina. |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| MX2022010340A (es) | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| JP2023520410A (ja) * | 2020-03-31 | 2023-05-17 | フレッド ハッチンソン キャンサー センター | Ｃｄ３３を標的にするキメラ抗原受容体 |
| CN115348973A (zh) | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| US20230133554A1 (en) | 2020-04-09 | 2023-05-04 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| CN113201063B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途 |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
| JP2024515181A (ja) * | 2021-04-19 | 2024-04-05 | ナンジン レジェンド バイオテック カンパニー，リミテッド | キメラサイトカイン受容体及びその細胞療法における使用 |
| CN113072648B (zh) * | 2021-06-04 | 2021-08-24 | 诺未科技（北京）有限公司 | 一种靶向afp的肝癌疫苗 |
| CN113416708A (zh) * | 2021-06-10 | 2021-09-21 | 深圳市先康达生命科学有限公司 | 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用 |
| US20230086030A1 (en) * | 2021-08-30 | 2023-03-23 | Industry-Academic Cooperation Foundation, Yonsei University | Lymphoma cell-specific drug delivery system for prevention or treatment of lymphoma and method for preparing same |
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| JP2025515134A (ja) * | 2022-05-04 | 2025-05-13 | アーリ インコーポレイテッド | 疾患細胞の位置を決定するおよび／または疾患細胞を処置するために表面発現可能な活性化可能エピトープを使用する方法 |
| CA3259305A1 (en) * | 2022-07-11 | 2024-01-18 | Sonoma Biotherapeutics, Inc. | RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE |
| JP2025529913A (ja) * | 2022-08-26 | 2025-09-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラサイトカイン受容体及び使用方法 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| WO2024123835A1 (en) * | 2022-12-06 | 2024-06-13 | Dynamic Cell Therapies, Inc. | Engineered switches for immune cell activity and methods of use thereof |
| CN120981484A (zh) | 2023-01-23 | 2025-11-18 | 汉诺威医学院 | 抗entpd3嵌合抗原受体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| AU2024240076A1 (en) | 2023-03-20 | 2025-08-28 | Autolus Limited | A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024238287A1 (en) * | 2023-05-12 | 2024-11-21 | Chimeris Uk Ltd. | Dual blocking and chimeric cytokine receptor |
| GB202309704D0 (en) | 2023-06-27 | 2023-08-09 | Autolus Ltd | Chimeric transmembrane protein |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2164623A1 (en) | 1993-06-07 | 1994-12-22 | Robert Enrico Pacifici | Hybrid receptor molecules |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| WO1999060120A2 (en) * | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| EP1399472B1 (en) * | 2001-03-09 | 2009-06-03 | ZymoGenetics, Inc. | Soluble heterodimeric cytokine receptor |
| CN1659274A (zh) * | 2002-04-19 | 2005-08-24 | 津莫吉尼蒂克斯公司 | 细胞因子受体 |
| JP2004113062A (ja) | 2002-09-25 | 2004-04-15 | Teruyuki Nagamune | キメラ受容体を有する動物細胞とその利用 |
| CN101027079B (zh) * | 2004-10-12 | 2011-08-17 | 美国蛋白质公司 | 嵌合蛋白 |
| WO2007115230A2 (en) | 2006-03-30 | 2007-10-11 | University Of Medicine And Dentistry Of New Jersey | A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| WO2008045437A2 (en) * | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| RU2522004C2 (ru) | 2012-04-10 | 2014-07-10 | Владимир Константинович Боженко | Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения. |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| GB201405845D0 (en) * | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| IL281428B2 (en) | 2018-09-27 | 2024-10-01 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-08-20 GB GBGB1514875.2A patent/GB201514875D0/en not_active Ceased
-
2016
- 2016-08-19 CA CA2995785A patent/CA2995785A1/en not_active Abandoned
- 2016-08-19 WO PCT/GB2016/052564 patent/WO2017029512A1/en not_active Ceased
- 2016-08-19 JP JP2018509549A patent/JP2018523485A/ja not_active Withdrawn
- 2016-08-19 MX MX2018002042A patent/MX2018002042A/es unknown
- 2016-08-19 EP EP23216609.0A patent/EP4338756A3/en active Pending
- 2016-08-19 EP EP18189793.5A patent/EP3438123A1/en active Pending
- 2016-08-19 KR KR1020247017118A patent/KR20240093884A/ko active Pending
- 2016-08-19 BR BR112018003308-1A patent/BR112018003308A2/pt not_active Application Discontinuation
- 2016-08-19 AU AU2016308618A patent/AU2016308618B2/en active Active
- 2016-08-19 SG SG10201909759U patent/SG10201909759UA/en unknown
- 2016-08-19 RU RU2018109350A patent/RU2018109350A/ru unknown
- 2016-08-19 HK HK18111554.5A patent/HK1252161A1/zh unknown
- 2016-08-19 CA CA3091907A patent/CA3091907C/en active Active
- 2016-08-19 US US15/753,486 patent/US10800854B2/en active Active
- 2016-08-19 IL IL270207A patent/IL270207B2/en unknown
- 2016-08-19 MX MX2019013204A patent/MX421045B/es unknown
- 2016-08-19 KR KR1020187007751A patent/KR102669749B1/ko active Active
- 2016-08-19 CN CN201680046834.3A patent/CN108350047A/zh active Pending
- 2016-08-19 CN CN201911010436.8A patent/CN110724200B/zh active Active
- 2016-08-19 EP EP16756758.5A patent/EP3337814A1/en active Pending
-
2018
- 2018-01-30 IL IL257234A patent/IL257234A/en unknown
- 2018-02-15 CL CL2018000415A patent/CL2018000415A1/es unknown
- 2018-08-27 US US16/113,224 patent/US10800855B2/en active Active
-
2019
- 2019-04-23 CL CL2019001107A patent/CL2019001107A1/es unknown
- 2019-06-19 JP JP2019113625A patent/JP6979423B2/ja active Active
- 2019-06-26 ZA ZA2019/04156A patent/ZA201904156B/en unknown
-
2020
- 2020-08-20 US US16/998,756 patent/US11479613B2/en active Active
- 2020-08-20 US US16/999,012 patent/US11479614B2/en active Active
- 2020-12-01 JP JP2020199336A patent/JP7603426B2/ja active Active
-
2022
- 2022-07-26 US US17/815,110 patent/US12234295B2/en active Active
- 2022-11-07 JP JP2022178045A patent/JP2022190153A/ja not_active Withdrawn
-
2025
- 2025-01-21 US US19/033,252 patent/US20250333538A1/en active Pending
- 2025-03-21 JP JP2025047075A patent/JP2025089404A/ja active Pending
- 2025-03-21 JP JP2025047074A patent/JP2025089403A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021035395A5 (https=) | ||
| JP2019150066A5 (https=) | ||
| JP7266117B2 (ja) | クローディン１８．２を標的とする抗体又はキメラ抗原受容体 | |
| CN110662560B (zh) | 改进的抗原结合受体 | |
| CN110121505B (zh) | 嵌合抗原受体和表达其的自然杀伤细胞 | |
| CN109069537B (zh) | 共刺激结构域中具有重复结合基序的car | |
| JP2018523485A5 (https=) | ||
| CN111560072B (zh) | 抗人msln抗体以及靶向msln的免疫效应细胞 | |
| AU2018379502B2 (en) | Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same, and use thereof | |
| JP2019535262A5 (https=) | ||
| JP2018523484A5 (https=) | ||
| JP2018532407A5 (https=) | ||
| BR112021007334A2 (pt) | anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo | |
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| CN114149506B (zh) | 一种抗cd22抗体及其应用 | |
| KR20230010188A (ko) | 항-IL13Rα2 항체, 이의 항원 결합 단편 및 용도 | |
| JP7394067B2 (ja) | がん患者における腫瘍抗原を検出するための診断アッセイ | |
| JP2023526234A (ja) | キメラ抗原受容体スペーサー | |
| JP2023524132A5 (https=) | ||
| TW202334226A (zh) | 改良之抗原結合受體 | |
| EP3730519B1 (en) | Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof | |
| CN115466328B (zh) | 抗pd-1人源化抗体或其抗原结合片段及其应用 | |
| JP2023520658A (ja) | 抗ｔｎ－ｍｕｃ１キメラ抗原受容体 | |
| JP2025512797A (ja) | 改善されたキメラ受容体 | |
| CN116217732A (zh) | 靶向cd22和cd19的双特异性抗体及其嵌合抗原受体和应用 |